Results 151 to 160 of about 15,405 (223)

Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody. [PDF]

Blood
Newton NM, Agrawal K, Odell AV, Tracy T, Hackett C, Eldrup A, Whitfield M, Martyanov V, Girardi M, Sefik E, Flavell RA, Odell ID.   +11 more
europepmc   +1 more source

Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma Mimic. [PDF]

Cureus
Shammas R, Gudino-Rosales S, Kneiber D, Sarantopoulos GP, Aung T.   +4 more
europepmc   +1 more source

Histopathological and molecular analysis in dermis and epidermis of patients with systemic and localized scleroderma. [PDF]

North Clin Istanb
Sozeri B, Turkmen S, Atikan BY, Aktug H.
europepmc   +1 more source

Editorial: Understanding scleroderma: symptoms, causes, treatment options, and advanced diagnostic techniques. [PDF]

Front Immunol
Ostojic P.
europepmc   +1 more source

A phase 2b basket trial approach to treat multiple rare and fibrotic skin diseases. [PDF]

Front Med (Lausanne)
Volc S, Martus P, Schefzyk M, Günther C, Moinzadeh P, Susok L, Ferrer RA, Zago M, Pfeiffer C.   +8 more
europepmc   +1 more source

Juvenile Localized Scleroderma

, 2016
Francesco Zulian, Roberta Culpo
openaire   +1 more source

Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data. [PDF]

Med Sci (Basel)
Knighton K, Babun A, Turney J, Evans B, Sehgal I.   +4 more
europepmc   +1 more source

Ustekinumab-associated morphoea: systematic review of the literature and a real-world case. [PDF]

Drugs Context
Sousa M, Alvarenga JM, Lé AM, Torres T.
europepmc   +1 more source

Ischemic Necrosis of Bilateral Second Toes in the Absence of Macrovascular Disease or Primary Vasculitis: A Unique Case of Systemic Sclerosis Sine Scleroderma (ssSSc). [PDF]

Cureus
Elhaddad M, Elhaddad M, Corral V, Gant TF, Massaband BD.   +4 more
europepmc   +1 more source

Widespread skin sclerosis with impaired mobility. [PDF]

JAAD Case Rep
Huang ZZ, Ma JC, Huang P, Wang ZH, Guo Q, Wang LC.   +5 more
europepmc   +1 more source